Tzield Drug

FDA approves the first treatment to delay the onset of type-1 diabetes

The US Food and Drug Administration approved Thursday a biological therapy that delays type 1 diabetes onset.

It is the first treatment approved to prevent type 1 diabetes.

Intravenous infusion is the only way to administer the monoclonal antibody Teplizumab from ProventionBio or Sanofi. According to the manufacturer of the drug, it will cost $194,000 wholesale for a complete course of treatment. However, this price is unlikely to be what consumers would pay.

It works by reducing the body’s misdirected attack against its insulin-producing cells. This is because it protects these cells and gives people more time to control their insulin levels.

Tzield was shown to delay the progression of diabetes in clinical trials by just over two years. However, some study participants have seen longer-lasting benefits.

Mikayla Olsten was one of the people who was tested for diabetes. She was diagnosed after Mia, her nine-year-old sister, developed a sudden episode of diabetic ketoacidosis. Although there was no family history of diabetes, Mikayla didn’t have any symptoms. However, she did have four of the five autoantibodies doctors use to determine a person’s risk.

Tracy, Tracy’s mom, said that if someone has so many markers it doesn’t mean they will develop diabetes.

Mikayla was just 15 when she joined the study. She received teplizumab. Now 21, she is a senior at college. Tracy Olsten, Tracy Olsten’s doctor, says that her condition has not changed in six years.

A scientific statement by JDRF, the Endocrine Society, and the American Diabetes Association states that if a person has signs of autoimmune disease or episodes of uncontrolled sugar, their five-year risk of developing insulin-dependent symptoms is 75%. Nearly 100% of people are at risk for developing insulin-dependent diabetes in their lifetime.

Mikayla appears to have beaten those odds so far.

Tracy stated that managing Mia’s diabetes, who is dependent upon insulin, is a constant struggle.

“She does a lot of juggling, which is something that her peers do not have to do,” Tracy stated that she must plan for basketball games or practices on insulin control. She can’t go more than a few minutes without thinking about it. To be able to give Mikayla the chance to not have to think about it all day is incredible.”

“Screening becomes a very big problem”

Aaron Kowalski, the JDRF CEO, said that the biggest challenge in prescribing Tzield is finding patients who need it. People who do not have symptoms of the disease, but are interested in the drug, may not be aware that they are on the right track to receiving it.

Kowalski stated that screening is a major issue because about 85% of type 1 diagnoses are now in families without a family history. “Our goal is general population screening,” Kowalski said. Blood tests are used to identify markers of the disease.

People aged 8 or older with type 1 diabetes are eligible to use Tzield. Doctors can test for antibodies that attack insulin-producing beta cells in stage 2. However, their blood sugar levels are still normal.

Ashleigh Palmer, ProventionBio CEO, and co-founder stated that “the way industry and our medical system manage autoimmune diseases, especially type 1, is suboptimal.” We wait for the symptoms to present and then treat them chronically over a lifetime. It’s too late in type 1 diabetes because the symptoms are not present when they first appear.

Each infusion lasts 30-60 minutes and is part of a 14-day treatment.

Low white blood cell count and lymphocytes, rash, and headache were the most common side effects among trial participants.

Type 1 prevention is the first option

Type 1 diabetes is characterized by an immune system attacking beta cells of the pancreas, which produce insulin. This hormone helps blood sugar enter cells and be used for energy. It can occur for many years before symptoms of diabetes develop. Blood sugar can build up and cause muscle and fat to be broken down.

Palmer states that Tzield prevents the disease from manifesting by stopping the progression of the autoimmune disease and the destruction of beta cells. The treatment reboots the immune system and preserves beta cell function.

“We have no preventative measure against type 1 diabetes at this time, and this is despite [the National Institutes of Health] funding hundreds of million dollars over the past 20-plus years of TrialNet, which has tested many, many different items, including this,” stated Dr. Robert Gabbay who is chief scientific and medical officer of the American Diabetes Association. “Finally, there’s something that delays type 1 diabetes from the onset, and it is so exciting.”

Type 1 is not a preventable disease like type 2 diabetes. Instead, it can be managed with lifestyle changes such as losing weight and exercising.

Palmer stated that “For some reason, we don’t screen type 1 diabetes” despite biomarkers showing that the autoimmune disease process has already begun. Palmer stated that the drug could be used to encourage the medical system’s implementation of population-based screening in routine childhood well visits to prevent the disease from arising.

Tzield would allow doctors to screen family members of patients with type 1 diabetes for antibodies. The treatment will be delayed if the antibody levels are too high or if the person is at risk of developing diabetes.

“If someone has type 1, the most common question is, “Well, what about my baby?” Gabbay stated that type 1 is a very rare condition.

Potential to make a difference in the lives of millions

It is possible to have serious consequences if you wait for a type 1 diabetes diagnosis.

Type 1 diabetes can cause significant impairments in your quality of life. Palmer stated that type 1 diabetes is a chronic disease that will not go away.

Type 1 diabetics need to monitor their blood sugar levels throughout the day. This can affect how they exercise and eat. Diabetes ketoacidosis is a condition in which high blood sugar causes the body to begin to burn fat for fuel. This can lead to a buildup of acids called ketones in your bloodstream. This condition can cause death, hospitalization, or coma.

According to the American Diabetes Association (including 244,000 children and teenagers), there are approximately 1.9 million Americans with type 1 diabetes. Type 1 diabetes affects approximately 8% of all diabetics.

Olivier Bogillot from Sanofi, Sanofi’s US head of general medicines, said that type 1 occurs mainly in children and teens. You can alter the quality of life for both the families and the children by finding a treatment that delays the onset of the disease.

About The Author

Leave a Comment

Scroll to Top